Leadership
|
For the necessary data for your NDA, ANDA, or 505(b)(2) NDA submission, you can count on Camargo’s end-to-end drug development and regulatory expertise. Our executive team are accomplished leaders in the full spectrum of drug development (pre-clinical, manufacturing, clinical, regulatory and commercial) and have extensive experience working in and with pharmaceutical, biotech and contract services organizations. Our practical knowledge of both the science and the business strategy of drug development streamlines the drug’s path-to-market.
Kenneth V. Phelps
Ruth E. Stevens, PhD, MBA
William P. Stoltman, JD
Kathryn Wekselman, PhD, RN
Stacey A. Ayres, PhD
Cynthia F. Phurrough
Jaber Qasem, PhD |


